ABVX

Abivax S.A.

HealthcareBiotechnologyFRUSDPeers →Country macro →

$101.66

LiveJun 22, 2026

AI Brief

Market cap

$6.67B

52w range

5.69 – 148.83

P / E

—

EPS

—

Volume

2.19M

Revenue · FY

—

Overview Fundamentals Market Narrative & AI

Explain this page

Arphra AIPlain-English read on Abivax S.A.’s valuation

News pulse · 14d

8 storiesNegative -1.00All news →

06-09today

ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm5d
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm5d
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm11d
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm11d

AI Issuer Brief

Arphra AI

Loading cached brief…

Price

DB · prices_daily

1M 6M 1Y 5Y

Last

$99.15

Change

-11.04%

Period high

$132.91

Period low

$72.50

Period start

$111.462026-02-02

Through 2026-06-18

Fair value

Football field →

Weighted blend

—

— vs spot

Recommendation

n/a

0 of 0 methods

Method spread

0bull0bear

±5% threshold

Analyst PT consensus: $123.43 (+21.41%)

Candlestick · 1Y

Open in chart workstation →

ABVX

99.15-11.04%

H 135.07L 69.81MA50 115.33MA200 —Avg vol 1.3M

Price change · trailing returns

Live

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
+2.53%	+4.14%	-16.67%	-15.52%	-26.72%	-24.61%	+1563.83%	+1124.82%	+1124.82%	+1124.82%	+1124.82%

Insider · 30d

History →

Bought

0 txns

Sold

0 txns

Net flow

+$0

Aftermarket

Live

Jun 18, 11:25 PM

Last trade

$100.00

10 sh

Bid

$98.00

50 sh

Ask

$103.68

20 sh

Spread

$5.680

Recent quarters

All financials →

Period	Revenue	Net income	EPS

Sector & industry today

Live

Sectors

Real Estate
+1.28%
Industrials
+1.01%
Basic Materials
+0.65%
Energy
+0.59%
Healthcare
+0.03%
Utilities
-0.09%
Financial Services
-0.18%
Communication Services
-0.56%
Technology
-0.77%
Consumer Cyclical
-0.83%
Consumer Defensive
-0.98%

Top industries (issuer's industry highlighted)

Biotechnology
+7.27%
Software - Services
-5.92%
Electronic Gaming & Multimedia
-3.76%
Financial - Mortgages
-3.51%
Software - Infrastructure
-3.12%
Electrical Equipment & Parts
+2.70%
Staffing & Employment Services
-2.69%
Apparel - Footwear & Accessories
-2.61%
Coal
-2.36%
Advertising Agencies
+2.35%
Engineering & Construction
+2.33%
Broadcasting
-2.30%

Analyst view

Consensus target

—

No price-target data returned for this ticker.

Recent actions

0 ↑0 ↓0 hold

No recent grade actions.

News

DB · news_items

Recent analyst activity

10 latest

Jun 03, 2026PT$136.00Abivax price target lowered to $136 from $176 at Wolfe ResearchWolfe Research
Jun 03, 2026GradeOutperform → OutperformAbivax (ABVX) PT Lowered to $136 at Wolfe ResearchWolfe Research
Jun 02, 2026PT$135.00Abivax price target lowered to $135 from $140 at TruistTruist Financial
Jun 02, 2026GradeOverweight → OverweightAbivax price target lowered to $132 from $145 at Morgan StanleyMorgan Stanley
Jun 02, 2026PT$132.00Abivax price target lowered to $132 from $145 at Morgan StanleyMorgan Stanley
Jun 02, 2026GradeUnderperform → NeutralWedbush upgrades Abivax to Neutral, lowers target to $90Wedbush
Jun 02, 2026PT$90.00Wedbush upgrades Abivax to Neutral, lowers target to $90Wedbush
Jun 02, 2026GradeOutperform → OutperformAbivax price target raised to $187 from $131 at CitizensCitigroup
Jun 02, 2026PT$90.00Jefferies Downgrades Abivax (ABVX) to HoldJefferies
Jun 02, 2026GradeHoldJefferies Downgrades Abivax (ABVX) to HoldJefferies

Peers

No peer list available for ABVX.

Total assets

—

Total debt

—

Cash & equiv

—

Operating CF

—

Free cash flow

—

Buybacks

—

Recent insiders

All →

Insider	Action	Shares	Value	Date
No open-market insider activity in the recent window.

Income statement · annual

Open Financials →

Period	Revenue	Op income	Net income	EPS	Net margin